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Aquaglyceroporins form the subset of the aquaporin water chan-
nel family that is permeable to glycerol and certain small, un-
charged solutes. AQP9 has unusually broad solute permeability
and is expressed in hepatocyte plasma membranes. Proteolipo-
somes reconstituted with expressed, purified rat AQP9 protein
were compared with simple liposomes for solute permeability. At
pH 7.5, AQP9 proteoliposomes exhibited Hg2-inhibitible glycerol
and urea permeabilities that were increased 63-fold and 90-fold
over background. -Hydroxybutyrate permeability was not in-
creased above background, and osmotic water permeability was
only minimally elevated. During starvation, the liver takes up
glycerol for gluconeogenesis. Expression of AQP9 in liver was
induced up to 20-fold in rats fasted for 24–96 h, and the AQP9 level
gradually declined after refeeding. No changes in liver AQP9 levels
were observed in rats fed ketogenic diets or high-protein diets, but
AQP9 levels were elevated in livers of rats made diabetic by
streptozotocin injection. When blood glucose levels of the diabetic
rats were restored to normal by insulin treatments, the AQP9 levels
returned to baseline. Confocal immunofluorescence revealed AQP9
immunostaining on the sinusoidal surfaces of hepatocyte plates
throughout the livers of control rats. Denser immunostaining was
observed in the same distribution in livers of fasted and strepto-
zotocin-treated rats. We conclude that AQP9 serves as membrane
channel in hepatocytes for glycerol and urea at physiological pH,
but not for -hydroxybutyrate. In addition, levels of AQP9 expres-
sion fluctuate depending on the nutritional status of the subject
and the circulating insulin levels.
The AQP9 cDNA was first isolated during efforts to clone ureatransporters by expression in oocytes (1). Expressed in testes,
leukocytes, and brain, AQP9 is abundant in liver (1) where it
resides in hepatocyte plasma membranes facing the sinusoids
(2–4). The coding sequence of AQP9 is more closely related to
AQP3 (5) and AQP7 (6), which are both permeated by glycerol
and water. This subset of proteins, referred to as aquaglycero-
porins, is functionally distinct from the water-selective homologs
AQP1, AQP2, AQP4, and AQP5 (7). The original studies of
Xenopus laevis oocytes expressing rat AQP9 reported perme-
ability to a wide range of 14C- or 3H-labeled solutes including
polyols, carbamides, purines, pyrimidines, nucleosides, and
monocarboxylates (1). Glycerol and urea permeability have been
confirmed with AQP9 oocytes (8), but studies of proteolipo-
somes reconstituted with purified AQP9 protein have not been
reported.
The physiological functions of AQP9 are uncertain. During
prolonged fasting, glycerol released from adipocytes via AQP7
may be taken up by the liver via AQP9 for gluconeogenesis.
Urea, a byproduct of amino acid deamination, and -hydroxy-
butyrate, an alternative fuel, may be released from liver via
AQP9. An elegant series of recent studies of adipocyte AQP7
and liver AQP9 mRNAs and promoters suggested that the genes
are coordinately regulated during fasting and type 1 diabetes
mellitus (9), but this has not been confirmed with studies of the
AQP7 and AQP9 proteins.
We undertook studies to define the permeation of proteoli-
posomes reconstituted with purified rat AQP9 protein and to
provide evidence that expression of AQP9 protein is altered in
rats during fasting and insulin deficiency. Our studies indicate
that AQP9 facilitates hepatocyte glycerol influx and urea efflux,
establishing a greater functional repertoire for AQP9 as a solute
channel with minor water transport capacity.
Materials and Methods
Plasmid Construction. Standard methods were used (10). pXG-
ev1-AQP9 was constructed with AQP9 cDNA prepared from rat
liver total RNA and inserted into the BglII site of pXG-ev1
(11). pYES2-AQP9 was made from pXG-ev1-AQP9 with rat
AQP9 amplified with primers 5EcoRA9 (5-AGAAACGAAT-
TCATGCCTTCTGAGAAGGAC-3) and 3XbaRA9 (5-
CTGGCCTCTAGACTACATGATGACACTGAG-3). The
product contained an EcoRI site at the 5 end and an XbaI site
at the 3 end. pYES2 vector (Invitrogen) encoding MGHHH-
HHHHHHHSSGHIEGRHEF between the HindIII and EcoRI
sites was digested with EcoRI and XbaI for ligation with AQP9.
Expression and Purification of AQP9. Rat AQP9 was purified from
protease-deficient (pep4) Saccharomyces cerevisiae expressing
pYES2-AQP9 (12, 13). Membranes were solubilized in 200 ml of
buffer A [100 mM K2HPO410% glycerol200 mM NaCl5 mM
2-mercaptoethanol3% octyl glucoside (N-octyl--D-glucopyr-
anoside, Calbiochem) and protease inhibitors (EDTA-free com-
plete protease inhibitor mixture tablets, Roche Biochemicals)]
and loaded on an Ni-NTA agarose column (nickel-charged
nitrilotriacetic acid, Qiagen, Valencia, CA), washed, and then
eluted with buffer A containing 100 mM and 600 mM imidazole.
AQP9 Proteoliposome Transport Studies. Purified AQP9 protein
was reconstituted with Escherichia coli polar lipid extract
(Avanti, Alabaster, AL) into proteoliposomes by dialysis at a
lipid to protein ratio of 100:1 overnight at 4°C vs. 100 volumes
of reconstitution buffer [RB; 50 mM Mops150 mM N-methyl-
D-glucamine (Calbiochem)1 mM NaN3 (Sigma) and protease
inhibitors (EDTA-free), pH 7.5] (12, 13).
AQP9 proteoliposomes and protein-free control liposomes
were analyzed by light scattering using a stopped-flow apparatus
(SF-2001, Kin Tek Instruments, University Park, PA) with a
dead time of 1 ms. Osmotic water permeability of proteolipo-
somes was measured at 4°C as described (13). Glycerol, urea, and
-hydroxybutyrate permeability were measured with proteoli-
posomes preequilibrated with solutes 15 min on ice, and
permeability was measured at 24°C as described (13). Some
proteoliposomes were reconstituted by dialysis in the presence of
DL--hydroxybutyrate (total osmolality 855 mosM). Second-
order rate constants were calculated; the first constant repre-
sents AQP9 transport and the second represents background
permeability.
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Oocyte Transport Studies. Capped cRNAs were synthesized in vitro
from linearized pXG-ev1 plasmids (11). Defolliculated X. laevis
oocytes were injected with 5 ng of cRNA or 50 nl of diethyl
pyrocarbonate-treated water. Injected oocytes were incubated
for 3 days at 18°C in 200 mosM modified Barth’s solution.
Osmotic water permeability (11) and 14C-labeled solute per-
meability methods were used (1). Nonisotopic solute perme-
abilities (Ps) were measured by placing oocytes in 200 mosM
modified Barth’s solution containing 100 mosM of solute,
causing water inf lux and oocyte swelling. Ps was calculated
from the oocyte surface area (S  0.045 cm2), initial oocyte
volume (Vo  9  104 cm3), the initial slope of the relative
volume increase d(VVo)dt, the total osmolality of the sys-
tem (osmtotal  200 mosM), and the osmotic solute gradient
(solout  solin) as follows: Ps  [osmtotal  Vo  d(VVo)dt]
[S  (solout  solin)].
Fig. 1. Solute permeability measurements of rat AQP9 or rat AQP4 in oocytes. X. laevis oocytes were injected with 5 ng of rat AQP9 cRNA, 5 ng of rat AQP4
(M23) cRNA, 2.5 ng of AQP4 plus 2.5 ng of AQP9 cRNA, or 50 nl of water and cultured for 3 days. (A) Osmotic water permeability (Pf) was assayed by transferring
oocytes from 200 to 70 mosM Barth’s solution, and swelling was monitored by videomicroscopy. Solute permeability was assayed by placing oocytes in isotonic
solution containing 100 mM indicated solute. The concentration gradient caused solute influx resulting in water influx and oocyte swelling. Data are mean 
SD from six oocytes. (B) Uptake of 14C-labeled solute was measured over 90 s at room temperature. Values represent mean  SD from 6–10 oocytes.
Fig. 2. Purification of rat AQP9 protein and measurement of solute transport in AQP9 proteoliposomes. (A) Coomassie-stained SDSpolyacrylamide gel (Left)
and anti-AQP9 immunoblot (Right) of purified AQP9 protein. (B) Permeability of AQP9 proteoliposomes (reconstituted from pure E. coli lipids and purified AQP9
protein) or control liposomes (reconstituted with no protein) were evaluated for permeability for glycerol, urea, DL--hydroxybutyrate, or water. For solute
transport measurement, proteoliposomes or liposomes containing the indicated solute were rapidly mixed with an equal volume of isotonic solution containing
sucrose as a nonpermeant osmolyte. The concentration gradient caused solute efflux resulting in osmotically driven water efflux and vesicle shrinkage measured
by light scattering. To measure inhibition of solute transport, proteoliposomes were incubated with 1 mM HgCl2 at least 15 min before measuring light scattering.
For water transport measurement, AQP9 proteoliposomes, AQP4 proteoliposomes, and control liposomes were subjected to an abrupt 50% increase in
extravesicular osmolality resulting in water efflux, and shrinking was measured by light scattering. The kinetics of 10 measurements were normalized and fitted
to a characteristic first- or second-order exponential equation dependent on the time course of water efflux.
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Animal Studies. Experimental protocols were approved by the
Institutional Animal Care and Use Committee and conform to
National Institutes of Health guidelines. Male 225- to 250-g
Sprague–Dawley rats (Taconic) in individual cages with free
access to water received standard rodent chow, 14% protein, and
6% fat (5P07, Purina); ketogenic diet, 91% fat and 9% protein
(96355, Harlan Teklad) (14); or 60% protein diet (5787, Purina).
Some rats were injected s.c. with human insulin (Sigma) at 5
unitskg. Streptozotocin (30 mgml, Sigma) in 50 mM NaCitrate
(pH 4.5) was injected i.p. at 100 mgkg into other rats; some were
injected s.c. with 13 unitskg NPH insulin (Humulin N, Eli Lilly)
at 0900 and 1800 hours. Rats were killed at 1300 hours. Glucose,
urea nitrogen, and -hydroxybutyrate concentrations were mea-
sured in serum (Sigma kits). Blood glucose was measured with
a OneTouch Ultra Blood glucose monitoring system (Lifescan,
Mountain View, CA).
Tissue Processing, Immunoblotting, and Microscopy. Tissues were
immediately placed on ice and homogenized, and membranes
were collected by centrifugation (15); 25 g of membrane
protein was analyzed by SDSPAGE (16); immunoblots were
reacted with 3.5 gml rabbit anti-rat AQP9 (Chemicon). Sam-
ple loadings were confirmed with Ponceau S (Sigma), and band
intensities were scanned with a MacBAS bioimaging analyzer
system (Fuji).
Control rats, rats fasted 4 days, or rats injected with strepto-
zotocin 9 days earlier were perfusion-fixed with 3% paraformal-
dehyde, in 0.1 M cacodylate buffer, via left ventricle and
prepared for paraffin embedding and immunohistochemistry
(17). Confocal laser microscopy (Leica DMRS) was performed
by using rabbit anti-rat AQP9 (Alpha Diagnostics) and goat
anti-rabbit secondary antibodies (Alexa 488, Molecular Probes),
and the images were merged with differential interference
contrast images.
Results
Permeability of AQP9 in Oocytes. X. laevis oocytes injected with
cRNAs encoding rat AQP9, AQP4, or both were compared with
oocytes injected with 50 nl of water. Coefficients of osmotic
water permeability (Pf) were determined from rates of swelling
after transfer from 200 to 70 mosM Barth’s solution. Water-
injected oocytes exhibited low water permeability, whereas the
Pf of AQP9 oocytes was increased 4-fold, AQP4 oocytes
20-fold, and AQP9 	 AQP4 oocytes 12-fold (Fig. 1A Left).
Coefficients of Ps were determined by measuring oocyte
swelling after transfer to isoosmotic Barth’s solution containing
100 mosM solute (glycerol, D- or L--hydroxybutyrate). Water-
injected oocytes failed to swell after transfer to glycerol, and
AQP4 oocytes exhibited minimal permeability (Fig. 1 A Right).
AQP9 oocytes exhibited increased glycerol permeability, but
permeability of the AQP9 	 AQP4 oocytes was 2-fold higher.
This synergistic response is presumed to represent rapid glycerol
influx through AQP9 followed by rapid water influx through
AQP4. D- and L--hydroxybutyrate permeabilities were too low
to measure accurately.
Solute permeabilities were also determined by measuring
14C-labeled solute uptake. At neutral pH, AQP9 oocytes exhib-
ited much higher permeability to 14C-urea and 14C-glycerol than
AQP4 oocytes (Fig. 1B). At pH 7.5, the permeability of AQP9
oocytes to the racemic mixture DL-14C--hydroxybutyrate was
too low to measure accurately. At pH 5.5, the permeability of
AQP9 oocytes for DL-14C--hydroxybutyrate was 10 times higher
than the AQP4 oocytes (Fig. 1B).
Permeability of AQP9 in Proteoliposomes. Oocytes express endog-
enous membrane proteins, so a defined system was used to
measure permeability of purified AQP9 protein. Rat AQP9
with a polyhistidine tag at the N terminus was expressed in
S. cerevisiae and purified. Coomassie staining and immunoblot-
ting of SDSPAGE showed a major band at 32 kDa and a
ladder of oligomers (Fig. 2A). Purified AQP9 and pure E. coli
lipids were reconstituted into resealed proteoliposomes for
comparison with control liposomes reconstituted from lipid
without protein.
Fig. 3. Effect of fasting and refeeding on AQP9 levels in liver. (A Upper)
Anti-AQP9 immunoblot of liver membranes from three rats after the indicated
time of fasting. (A Lower) Scanning densities of anti-AQP9 immunoblot. (B)
Average serum levels of glucose, urea, and -hydroxybutyrate from the same
rats. (C) After 96 h of fasting, rats were allowed access to food. (Upper)
Anti-AQP9 immunoblot of liver membranes from three rats after indicated
time of refeeding. (Lower) Scanning densities of anti-AQP9 immunoblot.
Values represent mean  SD from three rats.







AQP9 proteoliposomes loaded with glycerol, urea, or DL--
hydroxybutyrate were rapidly transferred by stopped-flow to
isoosmotic fluid containing sucrose as a nonpermeant osmolyte.
Permeable membranes release solute, causing water eff lux mea-
surable by light scattering. Glycerol permeability of AQP9
proteoliposomes was 63 times higher than liposomes and was
almost entirely blocked with 1 mM HgCl2 (Fig. 2B); urea
permeability of AQP9 proteoliposomes was 90 times higher than
liposomes. When exposed to a simple osmotic gradient, AQP9
proteoliposomes were only 1.4 times as permeable as liposomes.
At neutral pH, DL--hydroxybutyrate permeability of AQP9
proteoliposomes and liposomes was equivalent (Fig. 2B), even if
the proteoliposomes were reconstituted in the presence of
DL--hydroxybutyrate. Precipitations appeared when DL--
hydroxybutyrate permeability measurements were attempted at
pH 5.5 (not shown).
AQP9 Expression in Liver. AQP9 protein levels were increased in
liver of rats within 12 h of fasting (not shown). Continued fasting
for up to 96 h with free access to water caused incremental
increases in AQP9 levels (Fig. 3A). During this time, the average
glucose and urea concentrations decreased by approximately
half, whereas -hydroxybutyrate increased 4-fold (Fig. 3B). Liver
AQP9 levels increased in all five of our experiments, rising as
high as 20-fold above baseline. When rats fasted 96 h were refed,
levels of AQP9 in liver gradually declined after 3 days and
returned to baseline levels after 1 week (Fig. 3C).
Ketogenic and high protein diets did not alter liver AQP9
levels. Ketogenic diets increase serum concentrations of -
hydroxybutyrate (14), but after a week rats did not exhibit
changes in liver AQP9 despite a 20-fold increase in serum
-hydroxybutyrate (not shown). Rats fed a high protein diet for
a week did not exhibit changes in liver AQP9, despite a 4-fold
increase in serum urea (not shown).
Effects of Insulin on AQP9 Expression in Liver. A single injection of 5
unitskg regular insulin (rapid-acting) caused a reduction in AQP9
in liver after 24 h (Fig. 4A). To evaluate the chronic effects of
insulin, rats were injected with 100 mgkg streptozotocin to destroy
pancreatic -cells; control rats were injected with buffer. After 5
days, the streptozotocin-treated rats were divided into two groups:
one group was injected twice daily with 13 unitskg NPH insulin
(long-acting) for 4 days; the other group received no injections. By
5 days, the streptozotocin-injected rats were all frankly diabetic, and
by 9 days serum glucose levels were 8-fold higher than control
rats, whereas serum glucose levels were normal in streptozotocin-
injected rats treated with insulin (Fig. 4B). AQP9 expression in liver
was increased 2-fold in the livers of streptozotocin-injected rats
when compared with livers from control rats or streptozotocin-
injected rats treated with insulin (Fig. 4B). Changes in liver AQP9
expression were not observed in rats injected s.c. with 3 mgkg
dexamethasone or 450 gkg glucagon when compared with con-
trol buffer-injected rats (data not shown).
Confocal Immunofluorescence Microscopy of AQP9 in Liver. Consis-
tent with previous studies (2–4), distinct AQP9 immunolabeling
was observed exclusively in plasma membranes at the sinusoidal
surfaces of hepatocyte plates of livers from control rats (Fig.
5A). The overall distribution of AQP9 was similar in livers of
fasted animals, although the level of immunolabeling was dra-
matically increased throughout the lobules (Fig. 5B). Further-
more, weak staining of nonsinusoidal surfaces was observed, and
hepatocytes were of markedly smaller size. Similar changes were
observed after streptozotocin treatment (Fig. 5C).
Discussion
Because of potential physiological importance, we investigated
transport of water, glycerol, urea, and -hydroxybutyrate by
AQP9 (Fig. 1). Osmotic swelling assays in oocytes showed that
rat AQP9 transports water much less rapidly than a water-
Fig. 4. Effect of insulin on AQP9 levels in liver. (A) Insulin injection. (Top) Anti-AQP9 immunoblot of liver membranes from three rats killed 24 h after injection
of buffer or 5 unitskg regular insulin, as indicated. (Middle) Scanning densities of anti-AQP9 immunoblot. (Bottom) Average blood levels of glucose at death.
(B) Streptozotocin pretreatment followed by insulin injection. (Top) Anti-AQP9 immunoblot of liver membranes from three rats killed 9 days after injection of
buffer (control), 100 mgkg streptozotocin (STZ), or streptozotocin followed by 4 days of bidaily injections of 13 unitskg NPH insulin (STZ 	 ins). (Middle)
Scanning densities of anti-AQP9 immunoblot. (Bottom) Average blood levels of glucose at death. Values represent mean  SD from three rats.
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selective channel like AQP4. In contrast, isoosmotic swelling
assays confirmed that AQP9 oocytes, but not AQP4 oocytes,
transport glycerol. Rates of -hydroxybutyrate transport were
too low to measure accurately. These results were confirmed by
measuring uptake of 14C-urea and 14C-glycerol. At pH 7.5,
permeability of AQP9 oocytes to 14C--hydroxybutyrate was
negligible. At pH 5.5 (still above the pKa of 4.7), a modest
increase in permeability was detected.
Studies of purified AQP9 protein have not previously been
reported. Proteoliposomes reconstituted with purified AQP9
were highly permeable to glycerol and urea, whereas -hydroxy-
butyrate permeability was essentially the same as background,
and water permeability was only slightly above background (Fig.
2). Thus, AQP9 is much more permeable to glycerol and urea
than to water and is essentially impermeable to -hydroxybu-
tyrate at physiological pH levels.
In vivo studies of AQP9 protein have not previously been
reported. Fasting is known to increase blood glycerol levels, and
up-regulation of AQP9 was observed in liver as expected.
Moreover, AQP9 protein levels continued to rise in liver after
fasting up to 96 h, and refeeding caused a gradual return to
baseline levels (Fig. 3C). During starvation, the liver releases
-hydroxybutyrate and other ketone bodies to substitute for
glucose. Kidney and skeletal muscle use ketone bodies but do not
express AQP9 (2). Although AQP9 is expressed in brain, fasting-
induced changes in protein levels were not observed (not shown).
We investigated other metabolic states known to cause ele-
vations of serum -hydroxybutyrate or urea; however, levels of
AQP9 were not increased in liver. Other urea transporters (18)
and -hydroxybutyrate transporters (19) have been identified in
liver; the latter are up-regulated in brain of rats on ketogenic
diets (14) and in liver of fasted rats (not shown). The only known
mammalian glycerol channels or transporters are aquaporins 3,
7, and 9. AQP7 is not expressed in rat liver (20), and it is not
known whether AQP3 is up-regulated in situations where the
liver requires increased glycerol import. AQP7 is expressed in
adipose tissue (6), where the protein is believed to facilitate the
release of glycerol during fasting (21–23). Coordinated regula-
tion of genes encoding mouse AQP7 and AQP9 was recently
reported (9). This regulation is thought to maximize glycerol
release from adipocytes and glycerol uptake by the liver.
As during fasting, blood insulin levels are low in type 1 diabetes
mellitus. Injection of streptozotocin produces a well established
animal model of insulin-dependent type 1 diabetes (24). Compared
with control rats, streptozotocin-injected rats had elevated blood
glucose levels and significantly increased AQP9 protein levels in
liver. Treatment of streptozotocin-injected rats with long-acting
NPH insulin restored AQP9 to baseline (Fig. 4B). One day after
administering rapid-acting regular insulin to normal rats, AQP9
levels in the liver decreased 50%, even though blood glucose levels
had returned to normal (Fig. 4A). These results suggest that insulin
represses AQP9 expression in vivo.
It is not certain why AQP9 levels are reduced more slowly after
refeeding fasted rats than after insulin treatment (compare Figs.
3C and 4A). In the refed state, insulin levels presumably returned
to normal soon after initial refeeding, so it is likely that
additional metabolic signals, such as glucocorticoids, may com-
plicate the response. Glucocorticoid levels in the blood increase
during fasting and are required for the increased gluconeogen-
esis in starvation and diabetes (25, 26). In cultured hepatoma
cells, dexamethasone increased expression of AQP9, whereas
insulin and dexamethasone added together had little effect on
AQP9 protein levels (not shown). The human AQP9 promoter
contains a glucocorticoid receptor binding motif (27), but it is
not known whether elevated glucocorticoid levels persist pro-
portionally longer after longer fasts.
Glycerol is not normally an important gluconeogenic precur-
sor for humans after overnight fasting, but after fasting human
Fig. 5. Confocal laser immunofluorescence microscopy of AQP9 in rat liver.
(A) Distinct AQP9 immunolabeling is seen associated with hepatocytes in liver
from control rat. (B) Increased AQP9 immunolabeling associated with hepa-
tocytes close to central vein in liver from rat after 4 days of fasting or (C) 9 days
after streptozotocin injection. CV, central vein. Arrowheads show sinusoidal
surface. Bars indicate 40 m.







subjects for up to 3.5 days, as much as 21% of circulating glucose
is derived from glycerol (28), and fasted rodents have even higher
values of circulating glycerol (29, 30). Taken together, recently
published studies of AQP9 mRNA (9) and our studies of AQP9
protein strongly support the role for AQP9 expression in liver as
a molecular mechanism for maximizing glycerol influx and urea
efflux during states requiring increased gluconeogenesis.
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